Search details
1.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Breast Cancer Res
; 22(1): 89, 2020 08 14.
Article
in English
| MEDLINE | ID: mdl-32795346
2.
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
Genes Chromosomes Cancer
; 56(8): 589-597, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28316110
3.
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Breast Cancer Res Treat
; 149(3): 669-80, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25663547
4.
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Breast Cancer Res Treat
; 141(3): 397-408, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-24091768
5.
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Breast Cancer Res
; 11(5): R77, 2009.
Article
in English
| MEDLINE | ID: mdl-19874578
6.
Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis.
Science
; 363(6424): 270-275, 2019 01 18.
Article
in English
| MEDLINE | ID: mdl-30573544
7.
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
Mol Cancer Ther
; 17(5): 897-907, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29483214
8.
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Cell Rep
; 25(9): 2617-2633, 2018 11 27.
Article
in English
| MEDLINE | ID: mdl-30485824
9.
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.
Cancer Cell
; 31(2): 225-239, 2017 02 13.
Article
in English
| MEDLINE | ID: mdl-28196595
10.
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
Clin Cancer Res
; 20(13): 3507-20, 2014 Jul 01.
Article
in English
| MEDLINE | ID: mdl-24879796
11.
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Mol Cancer Ther
; 12(4): 509-19, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23395886
12.
BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition.
JCO Precis Oncol
; 22018.
Article
in English
| MEDLINE | ID: mdl-31799491
13.
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Anticancer Res
; 33(8): 2997-3004, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23898052
14.
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Mol Cancer Ther
; 11(9): 1978-87, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-22761403
Results
1 -
14
de 14
1
Next >
>>